Filter by faculty:

Found 29 matching student topics

Displaying 1–12 of 29 results

Interactive art

This suggested practice-based research project seeks, overall, to ask how interactive art engages audiences, how it is created and, depending on the applicant's interest and expertise, how it might be a collaborative effort between artist and technologist.ituated within the nascent area of interactive art, contributing new understandings and research into the form and design of interactive art works; and new insights into audience experience of interactive art.The project can engage with themes and theories in its exploration of interactive art …

Study level
PhD, Master of Philosophy
Faculty
Faculty of Creative Industries, Education and Social Justice
School
School of Design
Research centre(s)

Design Lab

Characterisation of a novel protein co-amplified with the n-MYC oncogene

The MYCN oncogene is amplified in a number of tumour types, including Neuroblastoma (NB) and Neuroendocrine Prostate Cancer (NEPC), where it is associated with worse patient prognosis, as compared to non-amplified tumours. However, the high expression of MYCN (encoding the n-MYC protein) alone in non-amplified tumours is associated with better patient prognosis and less aggressive disease. This suggests that other genes co-expressed in MYCN amplified tumours may be responsible for mediating the aggressive traits of n-MYC. Our team has identified …

Study level
Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

A novel molecular targeted therapy for anaplastic prostate cancer

In advanced PCa, where the cancer has spread into the bone and other organs, the emergence of treatment resistance remains inevitable. For decades the primary form of treatment in advanced PCa has been to target the production and actions of male sex hormones, androgens, the primary developmental and survival factor of prostate tissue. While these therapies result in tumour regression and cancer control, this is temporary and treatment resistance occurs, referred to as castrate resistant prostate cancer (CRPC). In the …

Study level
Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Testing a promising targeted therapeutic for triple-negative breast cancer

Triple-negative breast cancers (TNBC) are negative for Estrogen Receptor, Progesterone Receptor and HER2 expression, are clinically aggressive and cannot be treated with the available hormonal or targeted drugs used for other breast cancer subtypes. TNBC accounts for 15-20% of all invasive breast cancer and patients have increased risk of recurrence, mortality and metastases early during disease progression. There is an urgent clinical need to develop improved treatment strategies for these women since the median survival of patients with metastatic TNBC …

Study level
PhD, Master of Philosophy
Faculty
Faculty of Health
School
School of Biomedical Sciences

Investigating the role of Neuropilin-1 in Triple-Negative Breast Cancer metastasis and chemoresistance

Triple-negative breast cancers (TNBC) are negative for Estrogen Receptor, Progesterone Receptor and HER2 expression, are clinically aggressive and are unresponsive to the available hormonal or targeted drugs used for other breast cancer subtypes, so that TNBC patients rely mainly on chemotherapy. TNBC accounts for 15-20% of all invasive breast cancer and patients have increased risk of recurrence, mortality and early metastatic progression. Thus, there is an urgent clinical need to develop improved treatment strategies for TNBC. Neuropilin-1 (NRP1) is a …

Study level
PhD, Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Targeting a novel adaptive neovascular response of the tumour microenvironment to treat advanced prostate cancer

Prostate cancer (PCa) is a significant healthcare burden in Australia. Androgen signalling inhibition using androgen receptor (AR) antagonists is the principal systemic therapy for advanced PCa. Androgen receptors (AR) are an attractive therapeutic target due to their elevated expression in tumour epithelial cells and the retention of androgen signalling throughout the disease continuum.However, patients eventually develop resistance to treatment, and PCa cells metastasise to distant bone and visceral organs, representing an incurable stage of the disease. Understanding mechanisms that contribute …

Study level
PhD, Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Eribulin effects on epithelial mesenchymal plasticity and therapy response

This proposal builds on data showing reversal of TGFbeta- or 5FU-induced epithelial mesenchymal transition (EMT) in breast cancer cell lines in vitro and in vivo by eribulin (1, 2). Given the established relationship between EMT and therapy resistance in a wide range of scenarios (3-5), this potential of eribulin to reverse EMT and sensitise breast cancer cells to therapy has wide-reaching implications for improved patient outcomes. Evidence for this potential at the therapeutic level has been seen with in vitro …

Study level
Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Developing a precision oncology workflow for Osteosarcoma treatment

Osteosarcoma (OS) is the most common malignant bone tumour that primarily affects children and adolescents. With approximately 400 diagnosed cases/year in Australia, OS has the lowest survival rate of all solid cancers and is the leading cause of cancer-related death in Queensland adolescents. Unfortunately, 3 in 4 patients will not survive longer than five years following diagnosis with metastatic OS. Clinical “one size fits all” treatment strategies results in highly variable and unacceptably poor patient responses. Shockingly, both the OS …

Study level
PhD, Master of Philosophy
Faculty
Faculty of Health
School
School of Biomedical Sciences
Research centre(s)
Centre for Biomedical Technologies

Immunotherapy for autoimmune disease using T cell receptor-modified T-regulatory cells

Autoimmune diseases affect approximately 5% of Australians. Well known examples include type I diabetes, multiple sclerosis and rheumatoid arthritis. These diseases have unpleasant, and sometimes tragic, consequences for the affected person and are a costly burden on our health system. As treatment is often limited to managing symptoms, new therapies for autoimmune diseases are much desired.Many autoimmune diseases are tightly associated with inheritance of a particular allele at the major histocompatibility complex (MHC, also called human leucocyte antigen or HLA). …

Study level
Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Engineering Chimeric Antigen Receptor (CAR) T cell for the treatment of cancer

Chimeric Antigen Receptor (CAR) T cells are genetically modified immune cells that can recognise and kill cancer cells. They do so through the CAR, which recognises specific antigens expressed on cancer cells. CAR T cell therapy has emerged as an effective form of cancer immunotherapy in certain types of blood cancers and are now approved for use in patients. However, CAR T cell therapy can only benefit a very small proportion of cancer patients at present because it is very …

Study level
Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Determining the theapeutic efficiency of epigenetic drugs in ovarian cancer

Because cancer and many diseases arise from a combination of genetic propensity and the response of cells to external factors mediated through changes to the expression of key genes, it is important to understand epigenetic regulation. The epigenome is crucial to the changes of gene expression and there is now strong evidence that epigenetic alterations are key drivers of cancer progression. However, very few drugs targeting epigenetic modifiers have been successful, in part due to the lack of effective means …

Study level
Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Investigating immunosuppression downstream of activated FGFR2 in endometrial cancer

FGFR2 encodes two alternatively spliced isoforms that differ in their ligand binding domain and the combination of tissue specific expression of these isoforms and tissue specific expression of the FGF ligands is the foundation of normal paracrine signalling. Isoform switching from FGFR2b (inclusion of exon 8) to FGFR2c (inclusion of exon 9) occurs in tumorigenesis as it establishes an autocrine loop in epithelial cancer cells. Our lab has reported that FGFR2 activation by mutations or isoform switching is associated with …

Study level
PhD
Faculty
Faculty of Health
School
School of Biomedical Sciences

Page 1 of 3